3rd Edition of International Heart Congress
June 05-07,2025 | Hybrid Event
Angiotensin Receptor Blockers
Angiotensin Receptor Blockers (ARBs) play a crucial role in the field of cardiovascular medicine by targeting the renin-angiotensin-aldosterone system. These medications, also known as angiotensin II receptor antagonists, work by blocking the action of angiotensin II on specific receptors, thereby dilating blood vessels and reducing the workload on the heart. ARBs are commonly prescribed to manage conditions such as hypertension, heart failure, and diabetic nephropathy. By modulating the effects of angiotensin II, ARBs contribute to blood pressure regulation and the overall well-being of individuals with cardiovascular concerns. Their distinct mechanism of action and efficacy make ARBs a valuable class of drugs in the therapeutic arsenal against cardiovascular diseases, offering patients a targeted and effective approach to managing their health.
Shuping Zhong
University of Southern California, United States
Yong Xiao Wang
Albany Medical Center, United States
Yochai Birnbaum
Baylor College of Medicine, United States
Federico Benetti
Benetti Foundation, Argentina
Thomas Bernd Dschietzig
Relaxera GmbH & Co. KG, Germany
Mekhman N Mamedov
National Research Center for Preventive Medicine, Russian Federation
Narendra Kumar
HeartbeatsZ Academy, United KingdomSubmit your abstract Today
Title : Surgical fetal stem cells implantation in heart failure patients long term results at 14 years
Federico Benetti, Benetti Foundation, Argentina
Title : Exploring new biomarkers of cardiomyopathy
Shuping Zhong, University of Southern California, United States
Title : The development of human relaxin-2 for heart failure with preserved ejection fraction, HFpEF
Thomas Bernd Dschietzig, Relaxera GmbH & Co. KG, Germany
Title : Cancer and cardiovascular diseases: Common pathogenesis mechanisms and risk factors
Mekhman N Mamedov, National Research Center for Preventive Medicine, Russian Federation
Title : Pulse field ablation for atrial fibrillation complications: What do we know yet
Narendra Kumar, HeartbeatsZ Academy, United Kingdom
Title : Lipoprotein (a): The hidden cardiovascular risk
Syed Raza, Awali Hospital, Bahrain